TERT and neoplasm: Notwithstanding that rare BRAFK601E mutations might traduce a better outcome, it must be noted that high-risk mutations such as BRAF600E, TERT promoter or TP53 disqualify a tumor from being classified as NIFTP, thus warranting additional search for eventual invasive features or hidden papillae [18, 19].